The aim of the present study was to examine whether PCSK9 or LDLR levels associate with markers of subclinical CVD in RA patients and whether PCSK9 levels or PCSK9/LDLR ratio can predict high CVD risk in RA. This evidence concerns the gene LDLR and rheumatoid arthritis.